Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KP405 SAD and MAD Study in Healthy Participants and Parkinson's Disease Patients
NCT06189170Phase 1Completed
- Sponsor
- Kariya Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KP405 in Parkinson's disease (PD) (11 cohorts), sponsored by Kariya Pharmaceuticals. Primary endpoints: Adverse event reporting at 1 year, 12-lead electrocardiogram at 1 year and 14 more. Started Aug 2024; status: completed.
02
Drugs
KP405
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06189170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189170.